CRSP enters Tuesday's earnings report carrying one of the most crowded short positions in biotech — yet the bears have spent the past month quietly retreating.
Short interest is running at 20.6% of the free float, a level that keeps CRSP firmly in the top tier of heavily shorted Nasdaq names. That number has real weight: it peaked even higher in early July, when roughly 24.9 million shares were short, before dropping sharply around July 10. Since then, shorts have continued unwinding steadily — short interest is down 21% over the past month, a meaningful rotation away from an aggressive bear stance. The borrow market confirms the retreat. Cost to borrow is just 0.61%, barely above index-fund rates, and availability has loosened to 133% — meaning more than one share is available to lend for every share currently borrowed. That is a market telling you shorting CRSP is easy and cheap, the opposite of squeeze conditions.
The ORTEX short score, though, complicates that picture. It registers 78.5, placing CRSP near the 96th percentile of its universe on short-related pressure. That score reflects the stock's still-elevated short interest and days-to-cover of 11.6, not imminent squeeze dynamics. The stock has clawed back 6% on the week after a brutal month that erased 17%, closing at $49.57 on Monday. Options positioning is only modestly more defensive than usual — the put/call ratio is 0.54, slightly above its 20-day mean of 0.53 and well within normal range. Neither options traders nor the borrow market are pricing in a dramatic move.
The analyst community remains constructive but divided on the magnitude of the opportunity. Firms including HC Wainwright, Citizens, and Citigroup hold targets of $80-$82, pointing to more than 60% upside from current levels. Piper Sandler sits even higher at $110. The outlier is TD Cowen, the only Hold in the visible coverage, with a $45 target — below the current price. Bernstein, rated Market Perform, lifted its target to $56 in May, essentially a ceiling call for the bears. The mean target across the Street is $74.76, a spread that reflects genuine disagreement about the commercial trajectory of Casgevy, CRISPR's FDA-approved sickle cell therapy. Bulls point to expanded FDA approval for younger patients and the Vertex partnership as durable growth levers. Bears focus on execution risk, patent dependency, clinical-stage dilution risk, and a balance sheet burning cash — the price-to-book is 2.86 and the EV/EBITDA is deeply negative.
The single most notable ownership fact heading into the print is ARK Investment Management's position: 11.3 million shares, 11.5% of the company, with a reported net addition of 5.8 million shares in the latest filing through July. ARK is effectively the largest institutional conviction holder and its continued buying has provided a floor even as short sellers retreat. The earnings report will test whether Casgevy's commercial ramp is progressing fast enough to justify the Street's bullish targets — or whether the bears who have been covering were simply repositioning ahead of a print they expect to disappoint.
See the live data behind this article on ORTEX.
Open CRSP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
